Responses
Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
713 Nanrilkefusp alfa, a high-affinity IL-15Rβγ agonist, promotes an innate and adaptive anti-tumour inflammatory environment as single agent or combined with anti-PD-1 in patients with advanced cancers
Compose a Response to This Article
Other responses
No responses have been published for this article.
